University of Houston introduces institute to bring business solutions to health care industry

medical biz

UH's C. T. Bauer College of Business will house the newly launched Healthcare Business Institute. Photo via Getty Images

The University of Houston announced this month that it has now launched its new Healthcare Business Institute, which will work with medical and business leaders as well as students to find solutions to pressing issues in the health care industry, such as high costs, access to care and new innovative technologies.

The institute will be part of the university's C. T. Bauer College of Business and led by Ravi Aron, research director and professor of health care strategy and technology in the Bauer College Department of Decision & Information Sciences, and Dr. Edward Kroger, the administrative director of the center.

“Providers are facing increasingly limited reimbursement from the U.S. government, insurers and employers. The industry is, therefore, struggling with finding new ways to increase value by improving quality and decreasing cost,” Aron says in a statement. “This is complicated by the fact that the industry is the most heavily regulated in the country. While policy, regulations and the government all have roles to play, efficient care delivery also requires businesses–small, medium, large and startups-to play a significant role in delivering effective and efficient care.”

The institute plans to bring together stakeholders from device makers and pharmaceutical companies to angel investors and educators to address many of these issues. Faculty and partners will release impactful research on topics such as hospital operations, new health care technologies, AI and machine learning in hospital contexts, emerging financial models in health care and a number of other topics.

Research will be shared in a new practitioner-facing Knowledge Portal that will feature a journal, editorials, and other media components like blogs, videos and audio.

The HBI will also have an educational component, with formal degree-based and shorter non-degree tracts, as well as a masters program related to health care leadership. Multiple executive education programs are also in the works.

“This unique combination of researchers, educationists and students will also benefit by connecting to perhaps the world’s most diversified health care ecosystem,” Aron says in the statement.

And Houston is the right place to house such an institute, says Bauer College Dean and Cullen Distinguished Chair Professor Paul A. Pavlou.

“Technology, data, and AI are enabling unprecedented advances in medicine, and Houston’s impressive health care network presents an exciting opportunity for a Healthcare Business Institute,” Pavlou says in the release. “Not only is Houston home to the Texas Medical Center, UH is the only university in Houston that includes a large number of health care researchers at the Bauer College of Business, a world-ranked health law program at the UH Law Center, a computer science department with many distinguished research faculty, and a new College of Medicine."

“The opportunity for meaningful collaboration among health care researchers, industry leaders, and students through HBI will be a tremendous asset for Houston with the potential for local, national and global impact,” he continues.

Earlier this summer, UH announced plans to open a 70,000-square-foot innovation hub next to the M.D. Anderson Library on UH's main campus in 2025. It's slated to house a makerspace, the Cyvia and Melvyn Wolff Center for Entrepreneurship, the Energy Transition Institute, innovation programs, and Presidential Frontier Faculty labs and offices.

From Your Site Articles

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston brain health co. secures $6.5M for rare disease study

neuro funding

Houston-based Goldenrod Therapeutics, part of Fannin Partners' portfolio, has announced the initial close of a $6.5 million series seed preferred stock round.

The round was led by Ataxia Ventures and an affiliate of Fannin, according to a news release.

Goldenrod Therapeutics plans to use the funding to support manufacturing, formulation optimization, IND-enabling studies and a Phase I study of its drug to treat brain inflammation, known as 11h.

The study will consider how 11h, which blocks the enzyme PDE4, could treat Friedreich’s ataxia (FA), a rare genetic disease that affects movement, speech and balance. To date, other PDE4 inhibitors have proven to regulate neuroinflammation and neuronal signaling, but have had adverse gastrointestinal side effects or have not reached enough of the central nervous system, according to Goldenrod.

The company says its 11h is expected to have "broad applicability" with limited emetric side effects.

“Our 11h program is a next-generation, orally bioavailable, brain-penetrant PDE4 inhibitor, where researchers overcame longstanding limitations associated with earlier PDE4 inhibitors," Dr. Dev Chatterjee, CEO of Goldenrod, said in the news release. "We believe this creates the potential for a best-in-class therapy for Friedreich’s Ataxia and a potential foundation for development across multiple neurodegenerative and neuroinflammatory disorders.”

11h was first developed at the University of Nebraska Medical Center (UNeMed). Houston-based Fannin Partners in-licensed the product 2020 and landed SBIR Phase I funding to support its initial development for opioid use disorder soon after.

Goldenrod has also received funding to study 11h's effectiveness for multiple sclerosis, methamphetamine addiction and cocaine addiction.

Goldenrod says it is developing 11h to target a variety of neurological and inflammatory conditions, including Alzheimer's disease, multiple sclerosis, ALS, substance use disorders, Batten disease, pain and traumatic brain injury.

Elon Musk's SpaceX is about to make its debut on Wall Street

Money Moves

Elon Musk's rocket company SpaceX will make its debut on Wall Street Friday, June 12, and both institutional and retail investors are expected to gobble up the 555.6 million shares going up for sale at $135 apiece. Musk, already the world's richest man, could become its first trillionaire.

SpaceX is likely to become the biggest IPO ever, with proceeds of around $75 billion. SpaceX hopes to become the first company to send people to Mars. In fact, part of Musk’s future compensation depends on SpaceX eventually establishing a colony of at least 1 million people on the red planet.

Why SpaceX is going public now

In a video conference on Musk's social media platform X, he told JPMorgan CEO Jamie Dimon that people have suggested for the last 10 years that he take SpaceX public. He's doing it now because the company plans to put 100,000 next-generation Starlink satellites into orbit. Deploying AI data centers in space is a “massive new growth base and you need capital for that,” he said.

Going public provides access to the capital that SpaceX needs. But it also exposes it to more scrutiny from shareholders and more regulatory oversight. That includes filing quarterly financial reports, which critics say incentivizes short-term thinking over longer-term planning and creates unnecessary costs for a company. Securities regulators are currently soliciting public comment on a proposal to require public companies to file the financial reports only twice every year.

How the IPO impacts the company

Musk will hold the majority of a special class of shares, giving him control over decisions related to company strategy, finances and personnel. On the latter, because of his ownership of most of these Class B shares, the only person who can fire Musk as CEO is Musk.

The company credits Musk with being the “driving force” behind its growth, innovation and success. But what happens if Musk is no longer in the picture? SpaceX warns that the loss of Musk could disrupt its ability to execute its strategy as well as hurt its “reputation and relationships with customers, partners and other stakeholders.”

The company also warns that finding a replacement with the same skills and experience as Musk would be time-consuming, if not nearly impossible. As Wedbush Securities analyst Dan Ives wrote Wednesday, “At the end of the day Musk is SpaceX and SpaceX is Musk.”

What could make or break SpaceX

Currently in the test phase, the gigantic reusable Starship rocket is key to SpaceX realizing Musk's ambitions. Much of the commercial space business hinges on SpaceX developing Starship’s capability to be fully reusable and hearty enough for a quick turnaround between flights. If that doesn't happen, SpaceX warns that putting data centers and satellites in space will take longer and cost more money, meaning it risks customers bailing on the company.

Analysts say that by pioneering reusable rockets, SpaceX has established a clear lead on competitors such as Blue Origin, led by Amazon founder Jeff Bezos. The Starlink satellite business competes with, among others, AST SpaceMobile – which is relying on a SpaceX rocket to send its latest generation of satellites into orbit next week.

The prospectus filed last week says SpaceX’s biggest potential market is the sale of business-oriented artificial intelligence products designed to transform how people get work done. It’s an opportunity SpaceX predicts would be worth $22.7 trillion if it could somehow dominate rivals like Anthropic, OpenAI and Microsoft in a highly competitive industry. But the prospectus shows no clear path to profitability for the xAI business, which merged with SpaceX earlier this year.

Why Wall Street is paying attention

If the SpaceX IPO is as successful, the stock could quickly join the Nasdaq 100, a widely followed index that tracks the 100 largest non-financial companies in the composite. That's important because some popular funds, such as the $460 billion QQQ exchange-traded fund, mimic the index and will automatically buy whatever is listed in the index.

Nasdaq recently changed its rules to allow select companies to enter the Nasdaq 100 after just 15 trading days.

S&P Dow Jones Indices, on the other hand, is sticking to established and more traditional thresholds that will not allow SpaceX or other companies with gargantuan IPOs faster entry into its S&P 500 index. That means even high-profile companies will still need to wait for their stocks to trade a full 12 months before they can enter the index.

Companies want to be in the S&P 500 in particular because it's arguably the most important index on Wall Street, with trillions of dollars either mimicking it exactly or benchmarked against it. Vanguard's VOO fund that tracks the S&P 500 has roughly $950 billion invested in it, for example.

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME